U.S. Kidney Cyst Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Kidney Cyst Market
- ✓Market Size 2024: USD 2.4 billion
- ✓Market Size 2032: USD 3.6 billion
- ✓CAGR: 5.2%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Radiology Network Contracts: Medical device and imaging suppliers should secure contracts with U.S. hospital outpatient radiology networks before Q4 2026, targeting Bosniak IIF follow-up protocols. Early contracts lock in recurring scanner utilization and reimbursed follow-up volume ahead of competitor consolidation.
Kidney Cyst Care in the United States: Market Overview
The U.S. kidney cyst market is distinctive because its value is generated mainly by detection rather than treatment. Simple renal cysts appear on a large share of adult abdominal scans, and the Bosniak classification system determines whether a lesion is dismissed, monitored, or referred for intervention. Consequently, imaging services and follow-up surveillance account for most spending, while drugs and procedures serve a smaller, specialized patient pool.
Relative to global norms, U.S. spending is more imaging-intensive and more reliant on outpatient radiology, reflecting high CT and ultrasound utilization and fee-for-service reimbursement. Analyst estimates place 2024 U.S. spending at roughly USD 2.4 billion, with about 60% tied to imaging and surveillance, 25% to autosomal dominant polycystic kidney disease (ADPKD) pharmaceuticals, and the balance to percutaneous and laparoscopic cyst-directed procedures. Europe's publicly funded systems, by contrast, concentrate follow-up in fewer, centralized centers.
Growth Drivers in U.S. Kidney Cyst Care
Three country-specific drivers sustain demand. First, Medicare fee-schedule coverage for CT abdomen and pelvis (CPT 74160 with contrast, 74150 without) and renal ultrasound (CPT 76770) keeps incidental detection reimbursed, anchoring scan volume. Second, the PKD Foundation estimates roughly 600,000 Americans live with ADPKD, a population that requires lifelong cyst surveillance and kidney function monitoring.
Third, the FDA approved tolvaptan (Jynarque) in 2018 for rapidly progressing ADPKD, and Medicare Part D coverage has converted that approval into recurring drug spend. The NIDDK-funded Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) validated total kidney volume imaging as a progression marker, which expands imaging use in specialist nephrology clinics.
Market Restraints and Entry Barriers in the U.S.
Entrants face several barriers. The Jynarque REMS program requires liver function monitoring and restricts dispensing to specialty pharmacies, adding distribution complexity. Imaging and ablation devices require FDA 510(k) clearance under 21 CFR Part 807, and hospital capital purchasing runs through group purchasing organizations such as Vizient and Premier, which favor incumbents with multi-year contracts.
Pricing pressure intensifies as Medicare negotiated prices under the Inflation Reduction Act begin applying to high-spend Part D products. Most simple cysts are asymptomatic and never reimbursed for treatment, so procedural volumes stay small and cannot scale, which limits returns for device entrants and keeps cyst-directed procedures a niche category.
Market Opportunities in U.S. Kidney Cyst Care
Near-term entry points include AI-assisted Bosniak classification software, which reduces radiologist reading time on indeterminate lesions. Analyst estimates place the addressable U.S. spend on AI-assisted characterization at roughly USD 180 million in 2025, based on surveillance reads across outpatient radiology networks and hospital imaging departments.
Ambulatory surgery centers offer a second opening for minimally invasive laparoscopic deroofing, which shifts cases from inpatient settings to lower-cost sites of care. Analyst estimates put this procedural niche near USD 95 million. A third opening lies in ADPKD monitoring platforms that track total kidney volume longitudinally, addressable at roughly USD 60 million in specialist nephrology practices.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 2.4 billion |
| Market Size 2032 | USD 3.6 billion |
| Growth Rate (CAGR) | 5.2% |
| Most Critical Decision Factor | Reimbursement pathway for surveillance imaging and ADPKD drug coverage |
| Largest Region | South (Texas, Florida, and Georgia corridor) |
| Competitive Structure | Fragmented in imaging and procedures; concentrated in ADPKD pharmaceuticals |
Leading Market Participants
- Otsuka Pharmaceutical
- Vertex Pharmaceuticals
- Novartis
- GE HealthCare
- Siemens Healthineers
- Philips
- Canon Medical Systems USA
- Medtronic
- Boston Scientific
- Cook Medical
Regulatory and Policy Environment
The FDA's Center for Drug Evaluation and Research administers the Jynarque REMS, while the Center for Devices and Radiological Health clears imaging and ablation hardware through 510(k) submissions, with a 90 FDA-day review goal. AI characterization software follows FDA's predetermined change control plan guidance, finalized in 2024. The CMS Physician Fee Schedule sets annual payment for CPT imaging codes, and ICD-10-CM codes N28.1 (acquired renal cyst) and Q61.2 (autosomal dominant polycystic kidney) drive claims classification.
The Inflation Reduction Act (Public Law 117-169) authorizes Medicare to negotiate prices for selected Part D drugs, with negotiated prices effective from 2026. The NIH's National Institute of Diabetes and Digestive and Kidney Diseases funds CRISP and related ADPKD research. State certificate-of-need programs in New York and North Carolina can require approval before imaging or ambulatory surgery capital expansions, so entrants must confirm state requirements before committing equipment budgets.
Long-Term Outlook for U.S. Kidney Cyst Care
By 2032, U.S. kidney cyst care will be defined by longer surveillance pathways rather than more procedures. Bosniak-guided follow-up imaging will expand as AI-assisted reads lower cost per study, shifting spend toward software-enabled outpatient radiology networks. Total kidney volume imaging will increasingly anchor ADPKD management in specialist nephrology clinics.
Drug economics will shape the largest revenue pool. Jynarque's current position and the Medicare negotiation cycle will compress pricing, while pipeline programs at Vertex and Novartis will expand ADPKD treatment options. Procedural cyst treatment will remain niche, with sclerotherapy and deroofing concentrated in ambulatory surgery centers.
Frequently Asked Questions
Market Segmentation
- Hospitals
- Ambulatory Surgery Centers
- Outpatient Imaging Centers
- Nephrology Clinics
- Urology Practices
- Computed Tomography
- Ultrasound
- Magnetic Resonance Imaging
- Contrast-Enhanced Ultrasound
- ADPKD Pharmaceuticals
- Percutaneous Sclerotherapy
- Laparoscopic Deroofing
- Active Surveillance Only
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.